Results 101 to 110 of about 27,289 (199)

Spironolactone or Finerenone for Cardiovascular and Kidney Protection in Patients with Moderate CKD? [PDF]

Am J Cardiovasc Drugs
Georgianos PI, Leptokaridou-Mourtzila E, Kourtidou C, Kontogiorgos I, Roumeliotis A, Vaios V, Liakopoulos V.   +6 more
europepmc   +1 more source

Finerenone vs. spironolactone to reduce adverse outcomes in patients with cardiac-kidney-metabolic syndrome complicated by atrial fibrillation: findings from the Tianjin atrial fibrillation project. [PDF]

Eur Heart J Open
Tian X, Liu X, Zhao J, Han X, Gu T, Chen KY, Korantzopoulos P, Lip GYH, Liu T.   +8 more
europepmc   +1 more source

Mineralocorticoid receptor antagonists for the treatment of heart failure and kidney disease: a state-of-the-art review. [PDF]

Heart Fail Rev
Van Spall HGC, Vardeny O.
europepmc   +1 more source

Mineralocorticoid receptor antagonists in heart failure with sustained monomorphic ventricular tachycardia: comparative analysis of spironolactone versus eplerenone. [PDF]

Open Heart
Szakál I, Komlósi F, Tóth P, Arnóth B, Bohus G, Vámosi P, Szegedi N, Salló Z, Osztheimer I, Perge P, Orbán G, Kardos A, Merkely B, Gellér L, Nagy KV.   +14 more
europepmc   +1 more source

Spironolactone therapy in resistant hypertension comorbid with mild obstructive sleep apnea: A retrospective cohort study. [PDF]

Medicine (Baltimore)
Fang C, Ma B, Xiao N, Zhao H, Ren S.
europepmc   +1 more source

Chemical stability study of diuretics in a concomitant simple suspension with magnesium oxide. [PDF]

J Pharm Health Care Sci
Kato G, Mitome H, Terada M, Hidaka N, Tanaka M, Akira K.   +5 more
europepmc   +1 more source

Targeted proteomic analyses during combined angiotensin-converting enzyme inhibitor and mineralocorticoid receptor antagonist administration (CARDALIS®) in healthy dogs. [PDF]

J Vet Intern Med
Ward JL, Goodman J, Blondel T, Zdyrski C, Manson E, Merodio M, Lamers RP, Allenspach K, Guillot E, Mochel JP.   +9 more
europepmc   +1 more source

Apparent mineralocorticoid excess with a novel <i>HSD11B2</i> variant: longitudinal clinical and biochemical follow-Up. [PDF]

JCEM Case Rep
Nalluri BT, Kudugunti N, Sahay RK.
europepmc   +1 more source

Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Mechanistic Basis, Clinical Evidence, and Therapeutic Integration. [PDF]

Drugs Drug Candidates
Al-Horani RA, Goyal N.
europepmc   +1 more source

Left Atrial Volume Index and Left Ventricular Mass Index Determine the Benefits of Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. [PDF]

J Am Heart Assoc
Zang H, Jia C, Pan Y, Li X, Zhang Q.
europepmc   +1 more source